Header Logo

Connection

Sue Leurgans to Parkinson Disease

Back to Details
This is a "connection" page, showing publications Sue Leurgans has written about Parkinson Disease.
Sue Leurgans
Connection Strength
2.425
Parkinson Disease
  1. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.167
  2. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.163
  3. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.143
  4. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.140
  5. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.130
  6. Effects of Cerebrovascular and Lewy Body Pathology on Parkinsonian Signs in Community-Dwelling Older Adults. Neurology. 2023 08 15; 101(7):e754-e763.
    View in: PubMed
    Score: 0.117
  7. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
    View in: PubMed
    Score: 0.086
  8. Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease. Brain Pathol. 2018 07; 28(4):560-568.
    View in: PubMed
    Score: 0.079
  9. Urinary Incontinence, Incident Parkinsonism, and Parkinson's Disease Pathology in Older Adults. J Gerontol A Biol Sci Med Sci. 2017 Sep 01; 72(9):1295-1301.
    View in: PubMed
    Score: 0.078
  10. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63.
    View in: PubMed
    Score: 0.067
  11. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22.
    View in: PubMed
    Score: 0.063
  12. Associations between quantitative mobility measures derived from components of conventional mobility testing and Parkinsonian gait in older adults. PLoS One. 2014; 9(1):e86262.
    View in: PubMed
    Score: 0.061
  13. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.058
  14. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug; 28(9):1230-40.
    View in: PubMed
    Score: 0.057
  15. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol. 2012 Feb; 71(2):258-66.
    View in: PubMed
    Score: 0.053
  16. Cerebrovascular disease pathology and parkinsonian signs in old age. Stroke. 2011 Nov; 42(11):3183-9.
    View in: PubMed
    Score: 0.051
  17. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.050
  18. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.044
  19. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease? Clin Neurophysiol. 2009 Feb; 120(2):390-7.
    View in: PubMed
    Score: 0.043
  20. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.042
  21. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.042
  22. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.041
  23. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.037
  24. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.036
  25. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.036
  26. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.032
  27. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.032
  28. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb; 27(1):30-2.
    View in: PubMed
    Score: 0.030
  29. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.030
  30. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.029
  31. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.027
  32. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002 May 14; 58(9):1418-22.
    View in: PubMed
    Score: 0.027
  33. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.027
  34. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.026
  35. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep; 58(9):1379-82.
    View in: PubMed
    Score: 0.026
  36. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
    View in: PubMed
    Score: 0.025
  37. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.024
  38. Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):331-4.
    View in: PubMed
    Score: 0.024
  39. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol. 2000 Oct; 57(10):1461-3.
    View in: PubMed
    Score: 0.024
  40. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
    View in: PubMed
    Score: 0.024
  41. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord. 2000 Mar; 15(2):276-9.
    View in: PubMed
    Score: 0.023
  42. "On" freezing in Parkinson's disease: resistance to visual cue walking devices. Mov Disord. 2000 Mar; 15(2):309-12.
    View in: PubMed
    Score: 0.023
  43. Objective changes in motor function during placebo treatment in PD. Neurology. 2000 Feb 08; 54(3):710-4.
    View in: PubMed
    Score: 0.023
  44. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology. 2000 Jan 25; 54(2):458-62.
    View in: PubMed
    Score: 0.023
  45. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
    View in: PubMed
    Score: 0.021
  46. Vibratory thresholds and mobility in older persons. Muscle Nerve. 2009 Jun; 39(6):754-60.
    View in: PubMed
    Score: 0.011
  47. Association of daytime napping and Parkinsonian signs in Alzheimer's disease. Sleep Med. 2006 Dec; 7(8):614-8.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.